Search

Your search keyword '"Valent, Jason"' showing total 520 results
Start Over Author "Valent, Jason"
520 results on '"Valent, Jason"'

6. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Author

Chari, Ajai, Cornell, Robert, Gasparetto, Cristina, Karanes, Chatchada, Matous, Jeffrey, Niesvizky, Ruben, Lunning, Matthew, Usmani, Saad, Anderson, Larry, Chhabra, Saurabh, Girnius, Saulius, Shustik, Chaim, Stuart, Robert, Lee, Yihua, Salman, Zeena, Liu, Emily, and Valent, Jason

Subjects
Brutons tyrosine kinase inhibitor, carfilzomib, ibrutinib, multiple myeloma, Adenine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Oligopeptides, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Salvage Therapy, Survival Rate
Abstract

Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first-in-class, once-daily inhibitor of Brutons tyrosine kinase, an enzyme implicated in growth and survival of MM cells. Preclinical data suggest supra-additivity or synergy between ibrutinib and proteasome inhibitors (PIs) against MM. This phase 1/2b study evaluated the efficacy and safety of ibrutinib plus the PI carfilzomib and dexamethasone in patients with relapsed/refractory MM (RRMM). In this final analysis, we report results in patients who received the recommended phase 2 dose (RP2D; ibrutinib 840 mg and carfilzomib 36 mg/m2 with dexamethasone), which was determined in phase 1. The primary efficacy endpoint was overall response rate (ORR). Fifty-nine patients with RRMM received the RP2D (18 in phase 1 and 41 in phase 2b). These patients had received a median of three prior lines of therapy; 69% were refractory to bortezomib, and 90% were refractory to their last treatment. ORR in the RP2D population was 71% (stringent complete response and complete response: 3% each). Median duration of clinical benefit and median duration of response were both 6.5 months. Median progression-free survival (PFS) was 7.4 months, and median overall survival (OS) was 35.9 months. High-risk patients had comparable ORR and median PFS (67% and 7.7 months, respectively) to non-high-risk patients, whose ORR was 73% and median PFS was 6.9 months, whereas median OS in high-risk patients was 13.9 months and not reached in non-high-risk patients. The most common grade ≥3 hematologic treatment-emergent adverse events (TEAEs) were anemia and thrombocytopenia (17% each); the most common grade ≥3 non-hematologic TEAE was hypertension (19%). In patients with RRMM treated with multiple previous lines of therapy, ibrutinib plus carfilzomib demonstrated anticancer activity within the expected efficacy range. No new safety signals were identified and the combination was well-tolerated.

Published
2020

7. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Author

Lin, Cindy Hsin-Ti, primary, Tariq, Muhammad Junaid, additional, Ullah, Fauzia, additional, Sannareddy, Aishwarya, additional, Khalid, Farhan, additional, Abbas, Hasan, additional, Bader, Abbas, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, Anwer, Faiz, additional, Raza, Shahzad, additional, and Dima, Danai, additional

Published
2024
Full Text
View/download PDF

8. Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.

Author

Basali, Diana, primary, Zureigat, Hadil, additional, Nurse, Daniel Paul, additional, Elmaleh, Hassan, additional, Batah, Heya, additional, Adcock, Bridget, additional, Wei, Wei, additional, Dima, Danai, additional, Valent, Jason Neil, additional, Anwer, Faiz, additional, Samaras, Christy Joy, additional, Khouri, Jack, additional, Williams, Louis, additional, Raza, Shahzad, additional, van Heeckeren, Willem Jan, additional, and Mazzoni, Sandra Ann, additional

Published
2024
Full Text
View/download PDF

12. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.

Author

Dima, Danai, Hughes, Michael, Orland, Mark, Ullah, Fauzia, Goel, Utkarsh, Anwer, Faiz, Raza, Shahzad, Mazzoni, Sandra, Bhutani, Divaya, Williams, Louis, Lentzsch, Suzanne, Samaras, Christy, Valent, Jason, Chakraborty, Rajshekhar, and Khouri, Jack

Subjects
OVERALL survival, FAILURE (Psychology), SALVAGE therapy, TREATMENT failure, CARDIAC patients
Abstract

Background: Daratumumab's incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have suboptimal response to dara-based-therapy, have limited options. Objective: This study aimed to evaluate the outcomes of venetoclax-based therapy in t(11;14) positive AL patients who previously failed dara. Methods: Thirty-one patients with AL were included in this bi-institutional retrospective analysis. Results: Dara failure was due to inadequate response in 20 (65%) patients, haematologic relapse in 7 (22%), and both haematologic plus organ relapse in 4 (13%). Overall haematologic response rate to venetoclax-based therapy was 97%, with ≥ VGPR being 91%. Of the 19 evaluable patients with cardiac involvement, 14 (74%) achieved organ response. Of the 13 evaluable patients with renal involvement, 6 (46%) achieved organ response. With a median follow-up of 22 months, median time-to-next-treatment (TTNT) and overall survival (OS) were not reached. The 12- and 24-month TTNT rates were 74% and 56%, respectively. At data-cut-off, four patients had died, all from AL-related organ complications. The 12- and 24-month OS rates were 89% and 85%, respectively. Grade ≥3 adverse events occurred in 26% of patients, with 6% due to infections. Conclusion: These findings are encouraging for the use of venetoclax as salvage therapy post-dara failure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Author

Usmani, Saad Z, Hoering, Antje, Ailawadhi, Sikander, Sexton, Rachael, Lipe, Brea, Hita, Sandi Fredette, Valent, Jason, Rosenzweig, Michael, Zonder, Jeffrey A, Dhodapkar, Madhav, Callander, Natalie, Zimmerman, Todd, Voorhees, Peter M, Durie, Brian, Rajkumar, S Vincent, Richardson, Paul G, and Orlowski, Robert Z

Published
2021
Full Text
View/download PDF

16. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.

Author

Dima, Danai, Goel, Utkarsh, Sannareddy, Aishwarya, Ibeh, Nnaemeka, Ullah, Fauzia, Afrough, Aimaz, Mazzoni, Sandra, Mehdi, Ali, Rudoni, Joslyn, Raza, Shahzad, De Simone, Nicole, Williams, Louis, Khan, Adeel, Rashid, Aliya, Rice, Mikhaila, Ricci, Kristin, Samaras, Christy, Valent, Jason, Anderson, Larry D., and Anwer, Faiz

Subjects
PLASMA exchange (Therapeutics), TREATMENT effectiveness, MULTIPLE myeloma, IMMUNOGLOBULIN light chains, KIDNEY diseases
Abstract

Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell‐directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi‐institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, p = 0.006), and achievement of ≥VGPR (OR 21.7 p < 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, p = 0.09). With a median follow‐up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, p < 0.0001) and newly diagnosed disease (NDMM; HR 0.43, p = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab‐based regimens had a trend for better OS (p = 0.15), compared to other regimens, but the difference was not significant. At the end of follow‐up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab‐based therapies showing promise. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Davis, James, additional, Ahmed, Nausheen, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher Sun, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2024
Full Text
View/download PDF

19. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Adekola, Kehinde, additional, Anderson, Larry D., additional, Baljevic, Muhamed, additional, Baz, Rachid, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Costello, Caitlin, additional, D’Angelo, Christopher, additional, Derman, Benjamin, additional, Devarakonda, Srinivas, additional, Elsedawy, Noura, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Hillengass, Jens, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Hultcrantz, Malin, additional, Kang, Yubin, additional, Larson, Sarah, additional, Lee, Hans, additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Robinson, Timothy, additional, Rosenberg, Aaron, additional, Sborov, Douglas, additional, Schroeder, Mark A., additional, Sherbenou, Daniel, additional, Suvannasankha, Attaya, additional, Valent, Jason, additional, Varshavsky-Yanovsky, Asya Nina, additional, Snedeker, Jenna, additional, and Kumar, Rashmi, additional

Published
2024
Full Text
View/download PDF

20. Safety And Tolerability Of Cael-101, An Anti-amyloid Monoclonal Antibody, Combined With Anti-plasma Cell Dyscrasia Therapy In Patients With Light-chain Amyloidosis: 18-month Results Of A Phase 2 Study

Author

Valent, Jason, primary, Liedtke, Michaela, additional, Zonder, Jeffrey, additional, Molina, Maria A., additional, Udata, Chandrasekhar, additional, Ianus, Juliana, additional, Tripptree, John, additional, Catini, Julia, additional, and Quarta, C Cristina, additional

Published
2024
Full Text
View/download PDF

21. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Adekola, Kehinde, additional, Anderson, Larry D., additional, Baljevic, Muhamed, additional, Baz, Rachid, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Costello, Caitlin, additional, D’Angelo, Christopher, additional, Devarakonda, Srinivas, additional, Elsedawy, Noura, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Hillengass, Jens, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Hultcrantz, Malin, additional, Kang, Yubin, additional, Larson, Sarah, additional, Lee, Hans C., additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Robinson, Timothy, additional, Rosenberg, Aaron, additional, Sborov, Douglas, additional, Schroeder, Mark A., additional, Sherbenou, Daniel, additional, Suvannasankha, Attaya, additional, Valent, Jason, additional, Varshavsky-Yanovsky, Asya Nina, additional, Kumar, Rashmi, additional, and Snedeker, Jenna, additional

Published
2023
Full Text
View/download PDF

22. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Author

Dima, Danai, primary, Davis, James A., additional, Ahmed, Nausheen, additional, Jia, Xuefei, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2023
Full Text
View/download PDF

23. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Author

Davis, James A., primary, Dima, Danai, additional, Ahmed, Nausheen, additional, DeJarnette, Shaun, additional, McGuirk, Joseph, additional, Jia, Xuefei, additional, Raza, Shahzad, additional, Khouri, Jack, additional, Valent, Jason, additional, Anwer, Faiz, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2023
Full Text
View/download PDF

26. Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.

Author

Gasoyan, Hamlet, Anwer, Faiz, Casacchia, Nicholas J., Kovach, Jeffrey D., Valent, Jason, Ming Wang, Halpern, Michael T., and Rothberg, Michael B.

Subjects
STEM cell transplantation, MULTIPLE myeloma treatment, MULTIPLE myeloma diagnosis, COMBINATION drug therapy, PEARSON correlation (Statistics), SOCIAL determinants of health, RESEARCH funding, HEALTH insurance, QUESTIONNAIRES, LOGISTIC regression analysis, FISHER exact test, KRUSKAL-Wallis Test, MEDICARE, CANCER patients, RETROSPECTIVE studies, DESCRIPTIVE statistics, MULTIVARIATE analysis, CHI-squared test, MANN Whitney U Test, LONGITUDINAL method, CARBOCYCLIC acids, ANTHROPOMETRY, DATA analysis software, EVALUATION
Abstract

PURPOSE Little is known about the role of social determinants of health (SDOH) in the utilization of novel treatments among patients with newly diagnosed multiple myeloma (NDMM). METHODS This retrospective cohort study used Taussig Cancer Center's Myeloma Patient Registry to identify adults with NDMM between January 1, 2017, and December 31, 2021. Electronic health records data captured treatment with (1) triplet or quadruplet regimen and (2) lenalidomide during the first year after NDMM, and (3) stem-cell transplant (SCT) through December 31, 2022. Multivariable logistic regression models examined associations of demographic/clinical characteristics and SDOH with care patterns. RESULTS We identified 569 patients with median age at diagnosis of 66 years (IQR, 59-73); 55% were male, 76% White, 23% Black, 1.1% other races, insured by Medicare (51%), private payer (38%), Medicaid (8.3%), and self-pay/other (1.8%). In the multivariable models, self-pay/other payers (adjusted odds ratio [AOR], 0.15 [95% CI, 0.03 to 0.54]) was associated with lower odds of triplet or quadruplet regimen, compared with Medicare. Private insurance (AOR, 0.48 [95% CI, 0.27 to 0.86]) and self-pay/other payers (AOR, 0.16 [95% CI, 0.04 to 0.74]) had lower odds of lenalidomide. Black patients (v White; AOR, 0.47 [95% CI, 0.26 to 0.85]) and patients treated at regional hospitals (v Taussig Cancer Center; AOR, 0.27 [95% CI, 0.12 to 0.57]) had lower odds of SCT. The odds of receiving triplet or quadruplet regimen, lenalidomide, and SCT also varied by the year of NDMM. CONCLUSION Care for NDMM varied based on race, insurance type, year of diagnosis, and treatment facility. It may be useful to examine the impact of insurance-related characteristics and recent policy initiatives on care disparities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. P-330 The third-generation genetic engineered mouse model of late-stage multiple myeloma

Author

Lin, Jianhong, primary, Maqbool, Mohsin, additional, Emhoff, Kylin, additional, Alban, Tyler, additional, Hong, Hanna, additional, Irons, Eric, additional, Zhang, Wanying, additional, Maeda, Rie, additional, Ondrejka, Sarah, additional, Nakashima, Megan, additional, Anwer, Faiz, additional, Valent, Jason, additional, Yu, Jennifer, additional, Chan, Timothy, additional, Lathia, Justin, additional, and Zhao, Jianjun, additional

Published
2023
Full Text
View/download PDF

29. P-256 Initial report of a single institution experience with teclistamab for relapsed or refractory multiple myeloma including prior BCMA

Author

Faiman, Beth, primary, Dima, Danai, additional, Duco, Marissa, additional, Rice, Mikhaila, additional, Rudoni, Joslyn, additional, Anwer, Faiz, additional, Khouri, Jack, additional, Mazzoni, Sandra, additional, Raza, Shahzad, additional, Samaras, Christy, additional, Williams, Louis, additional, and Valent, Jason, additional

Published
2023
Full Text
View/download PDF

30. P-465 Global disparities in multiple myeloma: examining adverse events and drug toxicity trends

Author

Jaberi-Douraki, Majid, primary, Xu, Xuan, additional, Ramachandran, Remya Ampadi, additional, Faiman, Beth, additional, Anwer, Faiz, additional, Samaras, Christy, additional, Riviere, Jim, additional, Gedara, Nuwan Indika Millagaha, additional, Golmohammadi, Mobina, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Masood, Ashiq, additional, Mazzoni, Sandra, additional, Williams, Louis, additional, Zhao, Jianjun, additional, Valent, Jason, additional, Dima, Danai, additional, Abbas, Ata, additional, Cossor, Furha, additional, Khouri, Jack, additional, and Raza, Shahzad, additional

Published
2023
Full Text
View/download PDF

34. S204: SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY

Author

Valent, Jason, primary, Liedtke, Michaela, additional, Zonder, Jeffrey, additional, Molina, Maria Angelica, additional, Udata, Chandrasekhar, additional, Ianus, Juliana, additional, Tripptree, John, additional, Catini, Julia, additional, and Quarta, C Cristina, additional

Published
2023
Full Text
View/download PDF

36. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

Author

Dima, Danai, primary, Ullah, Fauzia, additional, Mazzoni, Sandra, additional, Williams, Louis, additional, Faiman, Beth, additional, Kurkowski, Austin, additional, Chaulagain, Chakra, additional, Raza, Shahzad, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, and Anwer, Faiz, additional

Published
2023
Full Text
View/download PDF

40. The Characteristics of Multiple Myeloma Patients Referred for CAR T-Cell Therapy

Author

Awada, Hussein, primary, Ali, Adel Hajj, additional, Sheu, Michael, additional, Patel, Meera, additional, Faiman, Beth, additional, Scott, Cynthia, additional, Mathur, Saveta, additional, Hamilton, Kimberly, additional, Samaras, Christy, additional, Mazzoni, Sandra, additional, Raza, Shahzad, additional, van Heeckeren, Willem, additional, Williams, Louis, additional, Valent, Jason, additional, Khouri, Jack, additional, and Anwer, Faiz, additional

Published
2023
Full Text
View/download PDF

41. Incidence of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Author

Awada, Hussein, primary, Ali, Adel Hajj, additional, Faiman, Beth, additional, Scott, Cynthia, additional, Mathur, Saveta, additional, Hamilton, Kimberly, additional, Samaras, Christy, additional, Mazzoni, Sandra, additional, Raza, Shahzad, additional, van Heeckeren, Willem, additional, Williams, Louis, additional, Valent, Jason, additional, Khouri, Jack, additional, and Anwer, Faiz, additional

Published
2023
Full Text
View/download PDF

42. Factors That Predict Early Relapse Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients

Author

Awada, Hussein, primary, Ali, Adel Hajj, additional, Faiman, Beth, additional, Scott, Cynthia, additional, Mathur, Saveta, additional, Hamilton, Kimberly, additional, Samaras, Christy, additional, Mazzoni, Sandra, additional, Raza, Shahzad, additional, van Heeckeren, Willem, additional, Williams, Louis, additional, Valent, Jason, additional, Khouri, Jack, additional, and Anwer, Faiz, additional

Published
2023
Full Text
View/download PDF

43. Analysis of Factors That Predict Progression Free and Overall Survival Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients

Author

Awada, Hussein, primary, Ali, Adel Hajj, additional, Faiman, Beth, additional, Scott, Cynthia, additional, Mathur, Saveta, additional, Hamilton, Kimberly, additional, Samaras, Christy, additional, Mazzoni, Sandra, additional, Raza, Shahzad, additional, van Heeckeren, Willem, additional, Williams, Louis, additional, Valent, Jason, additional, Khouri, Jack, additional, and Anwer, Faiz, additional

Published
2023
Full Text
View/download PDF

44. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs

Author

Dima, Danai, primary, Li, Ang, additional, Granat, Lauren M., additional, Dhillon, Puneet, additional, Chamseddine, Fatima, additional, Yalamanchali, Anirudh, additional, Mirzai, Saeid, additional, Wei, Wei, additional, Samaras, Christy J., additional, Valent, Jason, additional, Anwer, Faiz, additional, and Khouri, Jack, additional

Published
2023
Full Text
View/download PDF

46. Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Author

Awada, Hussein, primary, Hajj Ali, Adel, additional, Faiman, Beth M., additional, Winter, Allison, additional, Mazzoni, Sandra, additional, Samaras, Christy J., additional, Sauter, Craig S., additional, van Heeckeren, Willem J., additional, Dean, Robert M., additional, Pohlman, Brad, additional, Hill, Brian T., additional, Valent, Jason, additional, Sobecks, Ronald M., additional, Williams, Louis S., additional, Jagadeesh, Deepa, additional, Hamilton, Betty K., additional, Kalaycio, Matt, additional, Anwer, Faiz, additional, and Khouri, Jack, additional

Published
2022
Full Text
View/download PDF

47. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Author

Khouri, Jack, primary, Li, Hong, additional, Hansen, Doris K., additional, Sidana, Surbhi, additional, Shune, Leyla O., additional, DeJarnette, Shaun, additional, Anwer, Faiz, additional, Sborov, Douglas W, additional, Wagner, Charlotte B, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Valent, Jason, additional, Peres, Lauren C., additional, Hovanky, Vanna, additional, Simmons, Gary, additional, Dima, Danai, additional, Kalariya, Nilesh, additional, Afrough, Aimaz, additional, Kaur, Gurbakhash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher J., additional, Davis, James, additional, McGuirk, Joseph P., additional, Locke, Frederick L., additional, Baz, Rachid C., additional, Hamilton, Betty K., additional, Alsina, Melissa, additional, Sauter, Craig S., additional, Hashmi, Hamza, additional, and Patel, Krina, additional

Published
2022
Full Text
View/download PDF

49. Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Author

Awada, Hussein, primary, Hajj Ali, Adel, additional, Ali, Muhammad Faizan, additional, Faiman, Beth M., additional, Winter, Allison, additional, Mazzoni, Sandra, additional, Jagadeesh, Deepa, additional, Samaras, Christy J., additional, Williams, Louis S., additional, Sauter, Craig S., additional, van Heeckeren, Willem J., additional, Dean, Robert M., additional, Pohlman, Brad, additional, Hamilton, Betty K., additional, Hill, Brian T., additional, Valent, Jason, additional, Sobecks, Ronald M., additional, Kalaycio, Matt, additional, Khouri, Jack, additional, and Anwer, Faiz, additional

Published
2022
Full Text
View/download PDF

50. 1-Year Results from a Phase 2 Study to Determine Safety and Tolerability of Treating Patients with Light-Chain (AL) Amyloidosis with Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia

Author

Valent, Jason, primary, Liedtke, Michaela, additional, Zonder, Jeffrey A., additional, Tulchinskiy, Mark, additional, Udata, Chandrasekhar, additional, Ramirez, Girly, additional, Szymaniak, Kate, additional, Catini, Julia, additional, and Quarta, Candida Cristina, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results